Cited by 860Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and TreatmentBone health and treatments

The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.

Open access

Eisenberger, Mario A., Blumenstein, Brent A., Crawford, E. David, Miller, Gary, McLeod, David G., Loehrer, Patrick J., Wilding, George, Sears, Kathy, Culkin, Daniel J., Thompson, Ian M., Bueschen, Anton J., Lowe, Bruce A.·1998·New England Journal of Medicine

DOI 10.1056/nejm199810083391504

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Combined androgen blockade for the treatment of metastatic prostate cancer consists of an antiandrogen drug plus castration. In a previous trial, we found that adding the antiandrogen flutamide to leuprolide acetate (a synthetic gonadotropin-releasing hormone that results in medical ablation of testicular function) significantly improved survival as compared with that achieved with placebo plus leuprolide acetate. In the current trial, we compared flutamide plus bilateral orchiectomy with placebo plus orchiectomy. METHODS: We randomly assigned patients who had never received antiandrogen therapy and who had distant metastases from adenocarcinoma of the prostate to treatment with bilateral orchiectomy and either flutamide or placebo. Patients were stratified according to the extent of disease and according to performance status. RESULTS: Of the 1387 patients who were enrolled in the trial, 700 were randomly assigned to the flutamide group and 687 to the placebo group. Overall, the incidence of toxic effects was minimal; the only notable differences between the groups were the greater rates of diarrhea and anemia with flutamide. There was no significant difference between the two groups in overall survival (P=0.14). The estimated risk of death (hazard ratio) for flutamide as compared with placebo was 0.91 (90 percent confidence interval, 0.81 to 1.01). Flutamide was not associated with enhanced benefit in patients with minimal disease. CONCLUSIONS: The addition of flutamide to bilateral orchiectomy does not result in a clinically meaningful improvement in survival among patients with metastatic prostate cancer.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm199810083391504

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Studies on Prostatic Cancer: I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate
Huggins, C., & Hodges, C. V. (2002) · The Journal of Urology · doi:10.1016/s0022-5347(05)64820-3 · Cited by 3,856
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Surrogate endpoints in clinical trials: Definition and operational criteria
Prentice, R. L. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080407 · Cited by 2,057
Cancer statistics, 1997
Parker, S. L., Tong, T., Bolden, S., & Wingo, P. A. (1997) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.47.1.5 · Cited by 2,000
A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma
Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A., & Goodman, P. J. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908173210702 · Cited by 1,464
Self-citation
Leuprolide versus Diethylstilbestrol for Metastatic Prostate Cancer
The Leuprolide Study Group (1984) · New England Journal of Medicine · doi:10.1056/nejm198411153112004 · Cited by 622
The veterans administration cooperative urological research group's studies of cancer of the prostate
Byar, D. P. (1973) · Cancer · doi:10.1002/1097-0142(197311)32:5 · Cited by 595
Designs for group sequential tests
Fleming, T. R., Harrington, D. P., & O’Brien, P. C. (1984) · Controlled Clinical Trials · doi:10.1016/s0197-2456(84)80014-8 · Cited by 354
Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients
Prostate Cancer Trialists' Collaborative Group (1995) · The Lancet · doi:10.1016/s0140-6736(95)92163-x · Cited by 320
Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation
Rubinstein, L., Gail, M. H., & Santner, T. J. (1981) · Journal of Chronic Diseases · doi:10.1016/0021-9681(81)90007-2 · Cited by 270

Show all 25 references

Research works printed but not linked: 3

Huggins C, 1941, Cancer Res, 1, 293
10.1002/1097-0142(19931215)72:12+<3834::AID-CNCR2820721714>3.0.CO;2-Z · DOI
Eisenberger MA, 1994, Semin Oncol, 21, 613

Sorted by citations

Items 701–800 of 860

Docetaxel Based Treatment for Metastatic Castration-Resistant Prostate Cancer-our Early Experience
Ghagane, S. C., & Nerli, R. B. (2016) · Translational Biomedicine · doi:10.21767/2172-0479.100070 · Cited by 2
Risk stratification in oligometastatic prostate cancer
Morgans, A. K., & Hussain, M. (2017) · Current Opinion in Urology · doi:10.1097/mou.0000000000000439 · Cited by 2
Abiraterone is effective and should be considered for the treatment of metastatic castrate-naïve prostate cancer
Elkon, J. M., Millett, R. L., Millado, K. F., & Lin, J. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1444028 · Cited by 2
Clinical and prognostic significance of changes in haemoglobin concentration during 1 year of androgen‐deprivation therapy for hormone‐naïve bone‐metastatic prostate cancer
Ebbinge, M., Berglund, A., Varenhorst, E., Hedlund, P. O., Sandblom, G., & the Scandinavian Prostate Cancer Group (SPCG)‐5 Study Group (2018) · British Journal of Urology · doi:10.1111/bju.14227 · Cited by 2
Molecular Progression of Prostate Cancer: Androgens and Estrogens
Boorjian, S. A., & Tindall, D. J. (2012) · Humana Press eBooks · doi:10.1007/978-1-60761-259-9_7 · Cited by 2
Advances in the management of prostate cancer
Rosenthal, M. A. (2000) · Australian and New Zealand Journal of Medicine · doi:10.1111/j.1445-5994.2000.tb00861.x · Cited by 2
Second-Line Hormonal for Castrate-Resistant Prostate Cancer
Parihar, J. S., & Kim, I. Y. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800077-9.00057-8 · Cited by 2
Hormone Responsive Cancers
Santen, R. J., Duska, L., & Culp, S. H. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-2758-2.00029-9 · Cited by 2
Does Reimbursement Affect Physician Decision Making?
Bennett, C. L., & Stinson, T. J. (2000) · Cancer treatment and research · doi:10.1007/978-1-4757-3044-9_10 · Cited by 2
Re: Abiraterone and Increased Survival in Metastatic Prostate Cancer
Cheetham, P. J., & Petrylak, D. P. (2012) · European Urology · doi:10.1016/j.eururo.2012.01.036 · Cited by 2
A refugee with a supraclavicular lymph node An uncommon first presentation of carcinoma of the prostate
Bossink, A. W. J. (2001) · The Netherlands Journal of Medicine · doi:10.1016/s0300-2977(00)00095-4 · Cited by 2
Stepping-stones to the further advancement of androgen-deprivation therapy for prostate cancer
Nishiyama, T., Suzuki, K. Z., Yamana, K., 利根川, 悦., Wako, K., & Takahashi, K. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.2.259 · Cited by 2
Dual interim report of low-dose estramustine phosphate (EMP) monotherapy and very low-dose EMP therapy combined with LH-RH agonist for previously untreated advanced prostate cancer
Kitamura, T., Nishimatsu, H., Suzuki, M., Rafiq, M., Tomita, K., Takahashi, S., Takeuchi, T., Ohota, N., & Kameyama, S. (2005) · Journal of Applied Research · Cited by 2
Management of patients with an increasing prostate-specific antigen after radical prostatectomy
Khan, M. A., & Partin, A. W. (2004) · Current Prostate Reports · doi:10.1007/s11918-004-0038-1 · Cited by 2
Diagnosis and treatment of metastatic prostate cancer
Hu, X., Gallo, R. A., Stoyanova, R. S., Breto, A., Hara, D., Shi, J., Kryvenko, O. N., Abramowitz, M. C., Pra, A. D., Punnen, S., et al. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821789-4.00011-4 · Cited by 1
Random Error and the Role of Statistics
Rothman, K. J., Huybrechts, K. F., & Murray, E. J. (2024) · doi:10.1093/oso/9780197751541.003.0007 · Cited by 1
Management of Newly Diagnosed Metastatic Disease
Cowey, C. L., & Hutson, T. E. (2012) · Humana Press eBooks · doi:10.1007/978-1-60761-259-9_22 · Cited by 1
Docetaxel in Castration-Resistant Prostate Cancer: A Single-Centre Experience
Detti, B., Franceschini, D., Saieva, C., Brina, L. D., Baki, M., Meattini, I., Cataldo, V. D., Pasquetti, E. M., Furfaro, I. F., Mancuso, A. M., et al. (2015) · Cancer Investigation · doi:10.3109/07357907.2015.1060063 · Cited by 1
New approaches to the treatment of advanced prostate cancer.
Goluboff, E. T., Hirano, D., Thrasher, J. B., Stark, G., Miller, G. J., & Glode, L. M. (2001) · Europe PMC (PubMed Central) · Cited by 1
Self-citation
First-Line Hormonal Manipulation of Prostate Cancer
Venugopal, S., & Anderson, J. (2012) · Springer eBooks · doi:10.1007/978-3-642-27597-5_18 · Cited by 1
Screening and Early Detection for Genitourinary Cancer
Thompson, I. M., & Basler, J. W. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-737-6_4 · Cited by 1
Self-citation
Advancing Prostate Cancer: Treatment Options for the Urologist
Lowrance, W. T., & Chang, S. S. (2006) · Urologic Clinics of North America · doi:10.1016/j.ucl.2005.12.003 · Cited by 1
SUPPRESSIVE EFFECTS OF THE ANTIANDROGEN FLUTAMIDE ON ADRENAL ANDROGENS IN ADVANCED PROSTATE CANCER PATIENTS
Nakazato, H., Suzuki, K., Ito, K., Fukabori, Y., Kurokawa, K., & Yamanaka, H. (2001) · The Japanese Journal of Urology · doi:10.5980/jpnjurol1989.92.6 · Cited by 1
Androgen Deprivation Therapy for Advanced Prostate Cancer
Hammerer, P., & Manka, L. (2019) · Springer eBooks · doi:10.1007/978-3-319-42623-5_77 · Cited by 1
ADVERSE EFFECTS OF ANDROGEN DEPRIVATION THERAPY ON PATIENTS WITH PROSTATE CANCER AND ITS EFFECT ON OVERALL SURVIVAL
Shimabukuro, T., Ohmi, C., Nagamitsu, R., Shiraishi, K., & Matsuyama, H. (2021) · The Japanese Journal of Urology · doi:10.5980/jpnjurol.112.81 · Cited by 1
Comparative Analysis of PSA Nadir and Time to PSA Nadir on Clinical Outcomes in Patients with De Novo Spine Metastasis of Prostate Cancer Undergoing Androgen Deprivation Treatment (ADT) Only vs. ADT Intensification
Ngwa-Ebogo, T. T., Mbouché, L. O., Mbassi, A. A., Nchufor, R. N., Manka’a, M. L., Tamukum, M. H., Ashutantang, G., & Angwafo, F. (2024) · annals of urologic oncology · doi:10.32948/auo.2024.08.14 · Cited by 1
Deciphering versatile electrode materials in the electrochemical progressive processes for flutamide detection: A systematic review
Bhuvaneswari, C., Palpandi, K., Hariprasad, B. S., Dhayanithi, C. A., Raman, N., Periakaruppan, P., & Babu, S. G. (2024) · Microchemical Journal · doi:10.1016/j.microc.2024.112244 · Cited by 1
Cancer de prostate métastatique résistant à la castration : le point de vue de l’oncologue médical
Laramas, M., Costan, C., Tessier, A., & Farneti, D. (2011) · Médecine Nucléaire · doi:10.1016/j.mednuc.2011.04.003 · Cited by 1
CARCINOMA DELLA PROSTATA
Boccardo, F., Introini, C., Neumaier, C. E., Puppo, P., Ricci, F., Spina, B., Tomasello, L., Scientifiche, S., CARMIGNANI, G., Ciatto, S., et al. (2009) · Cited by 1
Evaluación del papel de la PET/TC con [68Ga]Ga-PSMA I&T en la evaluación de la respuesta a la terapia con docetaxel en pacientes con cáncer de próstata resistente a la castración
Özülker, T., & Özülker, F. (2020) · Revista Española de Medicina Nuclear e Imagen Molecular · doi:10.1016/j.remn.2020.01.004 · Cited by 1
Use of docetaxel in low- and high-burden metastatic hormone-sensitive prostate cancer: A systematic review and assessment of subgroup analyses
Gil‐Sierra, M. D., Rey, E. J. A. D., de la Lastra‐Romero, C. A., & Sánchéz‐Hidalgo, M. (2021) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552211037322 · Cited by 2
PROSTATE CANCER
Holstein, S. A., & Hohl, R. J. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3291-5.50071-8 · Cited by 1
Actions of Estrogenic Endocrine Disrupting Chemicals on Human Prostate Stem/Progenitor Cells and Prostate Carcinogenesis
Hu, D., Xie, L.-S., Li, Y., Prins, G. S., & Hu, W. (2015) · The Open Biotechnology Journal · doi:10.2174/1874070720151112e019 · Cited by 1
Molekulare Diagnostik beim Prostatakarzinom
Kamradt, J., Stöckle, M., & Wullich, B. (2003) · Der Urologe · doi:10.1007/s00120-003-0346-z · Cited by 1
Management of Metastatic Prostate Cancer
Meng, M. V. (2003) · doi:10.1007/978-1-4615-6505-5_15 · Cited by 1
The Case for Systemic Therapy Alone for Prostate Cancer
Sweeney, C. J. (2006) · The Journal of Urology · doi:10.1016/j.juro.2006.06.082 · Cited by 1
Present and Future Management of Prostate Cancer
White, R. D. (2000) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2000.15.121 · Cited by 1
Hormone therapy for prostate cancer
Koltz, L. (2007) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(07)70081-2 · Cited by 1
The androgen receptor as a therapeutic target in prostate cancer
Visakorpi, T. (2000) · Emerging Therapeutic Targets · doi:10.1517/14728222.4.1.65 · Cited by 1
[Clinical efficacy of treatment with low-dose flutamide in maximum androgen blockade therapy].
Shimizu, K., Kiyohara, H., Nakayama, J., Fujii, T., & Hosomi, M. (2001) · PubMed · Cited by 1
Chemo-hormonal therapy for Metastatic Hormone-sensitive Prostate Cancer: Clinical Trial Fantasy or Practice Reality?
Cha, T. (2015) · Urological Science · doi:10.1016/j.urols.2015.11.008 · Cited by 1
The Hormonal Management of Metastatic Prostate Cancer
Dorff, T. B., & Pinski, J. (2014) · Springer eBooks · doi:10.1007/978-0-85729-482-1_48 · Cited by 1
Stratégies de prise en charge du cancer de la prostate de stade T3
Soulie, M., Peneau, M., Richaud, P. M., & Ravery, V. V. (2008) · EMC - Radiologie et imagerie médicale - Génito-urinaire - Gynéco-obstétricale - Mammaire · doi:10.1016/s1879-8543(08)70656-6 · Cited by 1
Prostate cancer and life insurance.
Ae, M. (2000) · PubMed · Cited by 1
Stratégies de prise en charge du cancer de la prostate de stade T3
Soulie, M., Peneau, M., Richaud, P. M., & Ravery, V. V. (2008) · Annales d Urologie · doi:10.1016/s1762-0953(06)75040-3 · Cited by 1
GUANOSINE PHOSPHATE BINDING PROTEIN COUPLED RECEPTORS IN PROSTATE CANCER:
Raj, G. V., Barki‐Harrington, L., KUE, P. F., & Daaka, Y. (2002) · The Journal of Urology · doi:10.1097/00005392-200203000-00080 · Cited by 1
Expression and prognostic value of LRIG1 and the EGF-receptor family in renal cell and prostate cancer
Thomasson, M. (2009) · KTH Publication Database DiVA (KTH Royal Institute of Technology) · Cited by 1
Prise en charge thérapeutique des cancers de prostate
Beuzeboc, P. (2011) · Springer eBooks · doi:10.1007/978-2-8178-0021-9_27
Therapeutic Options for Benign Prostate Hyperplasia (BPH) and Prostatic Cancer
Leung, S. K. W., & McNeill, S. A. (2006) · Springer eBooks · doi:10.1007/3-540-33713-x_91
Prostate Cancer in Older Adults
Warlick, C. A., Weight, C., & Konety, B. R. (2014) · Springer eBooks · doi:10.1007/978-1-4614-9047-0_17
Palliative systemic antineoplastic therapy
Patel, S. M., & Fisch, M. J. (2001) · Cambridge University Press eBooks · doi:10.1017/cbo9780511642357.022
The regulatory role of osteoblasts in castration-resistant growth of prostate cancer
Thulin, M. H. (2015)
Prostate Cancer: Prognostic factors, markers of outcome and design of clinical trials
Collette, L. A. J. (2006) · RePub (Erasmus University Rotterdam)
Pharmacotherapy of Carcinoma Prostate - Current Scenario
Katiyar, D., Shankar, P., Verma, A., Sachan, A. K., & Dixit, R. (2013) · International Journal of Health Sciences and Research
Economic evaluation of change in clinical practice : methods for informing decisions about guidelines and implementation strategies
Hoomans, T. (2008) · Research Publications (Maastricht University) · doi:10.26481/dis.20081017th
Androgen Metabolism in Progression to Androgen-Independent Prostate Cancer
Balk, S. P. (2008) · doi:10.21236/ada502868
The Effect of Multiplicity of Metastatic Sites on Hormone Refractory Prostate Cancer
Halim, A. (2012) · DOAJ (DOAJ: Directory of Open Access Journals)
Novel Therapeutic Settings in the Treatment of Castration- Resistant Prostate Cancer
Alvarez, M., Gómez, J. M. F., Jalon, A., Miguelez, E., & Valle, F. (2013) · InTech eBooks · doi:10.5772/52288
Searching For SARA
Chapman, M. S., Chang, W. Y., Negro-Vilar, A. F., & Miner, J. N. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-767-3_14
Screening and Early Detection for Genitourinary Cancer
Potts, J. M. (2012) · Humana Press eBooks · doi:10.1007/978-1-62703-092-2_3
The changing landscape of hormonal therapy in castration-resistant prostate cancer
Dongre, A. S., Prabhash, K., & Noronha, V. (2012) · South Asian Journal of Cancer · doi:10.4103/2278-330x.103707
Anti-angiogenic therapy for prostate cancer: rationale and ongoing trials
Adesunloye, B. A., & Dahut, W. L. (2011) · Clinical Investigation · doi:10.4155/cli.11.157
The use of the EVITA algorithm for clinical assessment of novel agents used in prostate cancer, metastatic melanoma, and systemic lupus erythematosus
Szucs, T. D., Puri, D., & Blank, P. R. (2014) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-014-1698-6
Cancer avancé de la prostate et maladie osseuse métastatique
Caty, A., & Ravery, V. V. (2007) · ONCOLOGIE · doi:10.1007/s10269-007-0722-1
Therapie des kastrationsrefraktären Prostatakarzinoms
Rauchenwald, M., Krainer, M., Bauernhofer, T., Santis, M. D., HÖLTL, W., Kramer, G., Krause, S., Loidl, W. C., Oismüller, R., Reissigl, A. E., et al. (2012) · Wiener klinische Wochenschrift · doi:10.1007/s00508-012-0206-1
How the Addition of Hormones Improves Outcome: Hormone Therapy Alone in Locally Advanced Prostate Cancer
Mottet, N. (2004) · European Urology Supplements · doi:10.1016/j.eursup.2003.12.006
Estrategias terapéuticas del cáncer de próstata de estadio T3
Soulie, M., Peneau, M., Richaud, P. M., & Ravery, V. V. (2008) · EMC - Urología · doi:10.1016/s1761-3310(08)70049-5
Profile of bone metastases of prostate cancer among rheumatology inpatients in Lomé (Togo): A single center experience
Kakpovi, K., Oniankitan, O., Houzou, P., Fianyo, E., Koffi-Tessio, V. E. S., Tagbor, K. C., & Mijiyawa, M. (2013) · The Egyptian Rheumatologist · doi:10.1016/j.ejr.2013.09.003
Treatment of hormone sensitive prostate cancer
Boyle, H. J., & Droz, J. (2005) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(05)80292-7
Frailty Models for Quality of Life in Oncology
Troxel, A. B., & Esserman, D. A. (2004) · Journal of Biopharmaceutical Statistics · doi:10.1081/bip-120028511
Overall survival and biochemical failure-free survival comparison of brachytherapy treatment options versus external beam radiation therapy for both low and intermediate-risk prostate cancer: A propensity-score matched analysis
Smith, G. D. (2014) · Scholarship@Western (Western University)
Does the effectiveness of bicalutamide in reducing the risk of prostate cancer progression vary with lymph node status?
Albertsen, P. C. (2004) · Nature Clinical Practice Urology · doi:10.1038/ncpuro0002
Selecting a secondary treatment
Davis, N. B., Jani, A. B., & Vogelzang, N. J. (2003) · Urologic Clinics of North America · doi:10.1016/s0094-0143(02)00192-1
Pharmacotherapy for biochemical recurrences after therapy for localised prostate cancer
Ornstein, D. K., & Gaston, K. E. (2002) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.3.6.657
Actual Benefit of Chemo-Hormonal Therapy in Non-Castrate Metastatic Prostate Cancer
Şendur, M. A. N., Akıncı, M. B., Özdemir, N., Aksoy, S., Dede, D. Ş., Ulaş, A., Zengin, N., & Yalçın, B. (2015) · Future Oncology · doi:10.2217/fon.15.36
Early effects of castration therapy in non-malignant and malignant prostate tissue
Ohlson, N. (2005) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Androgen Controlled Regulatory Systems in Prostate Cancer -Potential new therapeutic targets and prognostic markers
Hammarsten, P. (2008) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Liver Metastases from Prostate Cancer
Zhang, J., Wang, H., & Yao, Y. (2014) · Springer eBooks · doi:10.1007/978-3-319-09293-5_15
JSM Clinical Oncology and Research
Onishi, T., & Sasaki, T. (2014)
Early vs. Delayed Hormonal Treatment in Locally Advanced or Asymptomatic Metastatic Prostatic Cancer Patient Dilemma: A Review
Prezioso, D. (2013) · Journal of Steroids & Hormonal Science · doi:10.4172/2157-7536.s5-001
Mechanism of Hic-5/ARA55 action, a novel stromal-specific nuclear receptor coactivator
Heitzer, M. D. (2005) · D-Scholarship@Pitt (University of Pittsburgh)
Determining the role of scavenger receptor class B type I as a source of cholesterol for de novo androgen synthesis in castration-resistant prostate cancer
Midha, A. (2015) · cIRcle (University of British Columbia) · doi:10.14288/1.0166529
New Developments in the Medical Management of Prostate Cancer REVIEW
Kohli, M., & Tindall, D. J. (2010)
Cabazitaxel
Schwartz, J. R., & Bottiglieri, S. M. (2012) · American Journal of Lifestyle Medicine · doi:10.1177/1559827612444253
Prostatakarzinom: Palliative Therapie
Huber, J. C., Brogsitter, C., Kotzerke, J., Hoelscher, T., Baumann, M. A., Fröhner, M., & Wirth, M. P. (2016) · Springer eBooks · doi:10.1007/978-3-642-39940-4_144
Androgen blockade in prostate cancer: a literature review
Kuribreña, A., Arroyo, C., Elena, S.-V., María, M.-P., & Manuel, C. (2012)
Androgen Deprivation for Men with PSA-Only Failure Following Radical Prostatectomy
Trump, D. L. (2004) · CRC Press eBooks · doi:10.1201/b14401-11
The Clinical Management of Prostate Cancer — The Medical Oncologist's Approach and Outcomes
Dreicer, R. (2003) · IMPERIAL COLLEGE PRESS eBooks · doi:10.1142/9781860945601_0029
Principles of Systemic Therapy
Muggia, F. M., & Ballas, M. S. (2009) · CRC Press eBooks · doi:10.3109/9780203092897-3
Examination of Prostate Cancer Stem-like Cell Associated Factors for their Contribution Towards the Development of Castration Resistant Prostate Cancer
Wong, N. (2016) · MacSphere (McMaster University) · doi:10.71548/15872
Beyond t he D evelopment o f H ealth-Related Q uality-of-Life (HRQOL) M easures: A C hecklist f or E valuating H RQOL Outcomes i n C ancer C linical T rials—Does H RQOL E valuation in P rostate C ancer R esearch I nform C linical D ecision M aking?
Efficace, F., Bottomley, A., Osoba, D., Gotay, C. C., Flechtner, H., & Zurlo, A. (2003)
Bone Metastases from Prostate Cancer: Hormonal Therapy
Zanardi, E., Cattrini, C., & Boccardo, F. (2016) · Springer eBooks · doi:10.1007/978-3-319-42327-2_10
Development and Validation of Methods for Detection of Prostate Cancer
Finne, P. (2000) · Työväentutkimus Vuosikirja
Chapter 6 Plumbagin and Prostate Cancer Therapy
Reshma, R. S., Nadhan, R., & Srinivas, P. (2016) · Traditional herbal medicines for modern times · doi:10.1201/9781315370156-7
First-Line Hormonal Manipulation: Surgical and Medical Castration with LHRH Agonists and Antagonists, Steroids, and Pure Antiandrogens
Gramann, T., & Schmid, H. (2017) · Springer eBooks · doi:10.1007/978-3-319-42769-0_21
Intermediate results of the observational program on the Eligard (45 mg) administration in the clinical practice
Matveev, V. B., & Markova, A. S. (2016) · Cancer Urology · doi:10.17650/1726-9776-2016-12-2-84-91
Androgen D eprivation a nd F our C ourses o f F ixed-Schedule Suramin T reatment i n P atients W ith N ewly D iagnosed Metastatic P rostate C ancer: A S outhwest O ncology Group S tudy
Hussain, M., Fisher, E. I., Petrylak, D. P., Wood, D. P., Small, E. J., Eisenberger, M. A., & Crawford, E. D. (2000)
Self-citation
The Role of Hormonal Treatment in Prostate Cancer
Hürmüz, P., Akyol, F. H., Gültekin, M., Yazıcı, G., Sarı, S. Y., & Özyiğit, G. (2017) · Springer eBooks · doi:10.1007/978-3-319-56114-1_20
Characterizing the Role of Insulin Signalling in Advanced Prostate Cancer
Sarkar, P. L. (2017) · Queensland University of Technology · doi:10.5204/thesis.eprints.110524
Re: Quality of Life in Advanced Prostate Cancer: Results of a Randomized Therapeutic Trial RESPONSE
Caubet, J.-F., Moinpour, C. M., Troxel, A. B., Lovato, L., Eisenberger, M., Blumenstein, B. A., & Crawford, E. D. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.4.381
Self-citation

Authors: Eisenberger, M. A., Blumenstein, B. A., Crawford, E. D., Miller, G., McLeod, D. G., Loehrer, P. J., Wilding, G., Sears, K., Culkin, D. J., Thompson, I. M., Bueschen, A. J., & Lowe, B. A.
Affiliations: Johns Hopkins Hospital (US)
SWOG Cancer Research Network (US)
University of Colorado Denver (US)
Walter Reed National Military Medical Center (US)
University of Wisconsin–Madison (US)
University of Oklahoma Health Sciences Center (US)
University of Alabama at Birmingham (US)
Oregon Health & Science University (US)
ORCID: Eisenberger, Mario A.
Blumenstein, Brent A.
Crawford, E. David
McLeod, David G.
Loehrer, Patrick J.
Wilding, George
Culkin, Daniel J.
Thompson, Ian M.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1998-10-08
Volume: 339
Issue: 15
Pages: 1036-1042
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199810083391504
OpenAlex: W2003985632
Cited by: 859
References: 25
Citations by year: 2026: 2 · 2025: 5 · 2024: 8 · 2023: 12 · 2022: 20 · 2021: 15 · 2020: 21 · 2019: 26 · 2018: 25 · 2017: 23 · 2016: 34 · 2015: 52 · 2014: 49 · 2013: 51 · 2012: 37
FWCI: 37.16
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (2u10ca038926-25)
National Cancer Institute (CA-32102, CA 42777, U10CA032102, U10CA042777, CA 38926)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Bone health and treatments
Keywords: metastatic prostate cancer, bilateral orchiectomy, flutamide, combined androgen blockade, leuprolide, antiandrogen therapy, overall survival, adverse effects, anemia, diarrhea
MeSH terms: Adenocarcinoma, Adult, Aged, Aged, 80 and over, Androgen Antagonists, Bone Neoplasms, Combined Modality Therapy, Double-Blind Method, Flutamide, Humans, Male, Middle Aged, Orchiectomy, Prostatic Neoplasms, Soft Tissue Neoplasms, Survival Analysis, Prostate-Specific Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks